Compare Cardinal Health Inc (CAH) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Lam Research Corporation — how do they compare? Cardinal Health Inc trades at $228.59 (market cap $53.89B), while Lam Research Corporation trades at $357.8 (market cap $432.82B). The key difference: Lam Research Corporation is far larger — about 8× Cardinal Health Inc's market cap, and Cardinal Health Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| CAH | LRCX | |
|---|---|---|
Market Cap | $53.89B | $432.82B |
Sector | Health | Technology |
52-Week High | $239.71 | $433.33 |
52-Week Low | $146.04 | $94.84 |
Enterprise Value | $58.87B | $431.81B |
Dividend Yield | 0.89% | 0.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Lam Research (LRCX) trades at $329.92, down 5.83% amid broader semiconductor sector volatility. The stock shows strong fundamentals with Q1 2026 EPS of $1.47 beating estimates by 8%, marking the third consecutive quarterly beat. Revenue grew 23.8% year-over-year to $18.44B in 2025, while net income margin expanded to 30.94%. Technical indicators show bearish momentum with the stock trading below key resistance at $332, though RSI at 22.63 suggests potential oversold conditions. Recent news highlights AI-driven demand for semiconductor equipment as a key growth catalyst.
LRCX presents a compelling long-term opportunity with 78% analyst buy ratings and $393 consensus price target (19% upside), though elevated P/E of 62.37 warrants caution. Strong cash flow generation ($6.17B operating cash flow) supports dividend payments and strategic investments. Risks include semiconductor cycle volatility and competitive pressures, but AI infrastructure spending provides durable tailwinds for the wafer fabrication equipment leader.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
